a manufacturer of medical imaging products
Industry PharmaceuticalsGeneric
This indicator may be signaling that LNTH's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 77 similar cases where LNTH's Momentum Indicator exceeded 0, and of them led to a successful outcome. Odds of Success:
Be on the lookout for a price bounce soon.
The Moving Average Convergence Divergence (MACD) for LNTH just turned positive on August 24, 2026. Looking at past instances where LNTH's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
Following a +0.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where LNTH advanced for three days, in 271 of 334 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
LNTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LNTH as a result. In 63 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LNTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for LNTH entered a downward trend on August 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. LNTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.990) is normal, around the industry mean (46.728). P/E Ratio (23.983) is within average values for comparable stocks, (93.360). LNTH's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.931). LNTH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (4.263) is also within normal values, averaging (176.516).